Eye-catching Success Story from Asia PharmaEngine is the first company from Taiwan receiving the US FDA approval for a locally-developed new oncology drug, ONIVYDE®.

OUR VISION IS TO BE A TOP TIER INNOVATIVE ONCOLOGY DRUG DEVELOPMENT COMPANY

PharmaEngine Inc. (TWO: 4162) is a commercial stage pharmaceutical company, we focus on the development of new medical treatment of cancer, as well as the commercialization of ONIVYDE® in Taiwan. Our headquarter is in Taipei, Taiwan with a wholly owned subsidiary PharmaEngine Europe, Sarl in Paris, France.

PharmaEngine has adapted the “no research, development only model (NRDO)” as well as “networked pharma model” for new drug development. Learn more…

Our portfolio includes ONIVYDE® approved for metastatic pancreatic cancer in Taiwan, US, EU, Australia, Canada, South Korea, and Singapore; PEP503 (NBTXR3) in a positive pivotal trial for soft tissue sarcoma; and PEP06 in preclinical development. Learn more…

Recent Events & Presentations

Recent News

Recent Financial Reports

TAIWAN STOCK EXCHANGE

Dividend Calendar

2018

EX-RIGHTS TRADING DAY EX-RIGHTS DATE
CASH DIVIDEND 1.000
STOCK DIVIDEND 0.000

2017

EX-RIGHTS TRADING DAY EX-RIGHTS DATE
CASH DIVIDEND 2.000
STOCK DIVIDEND 0.000

2016

EX-RIGHTS TRADING DAY EX-RIGHTS DATE
CASH DIVIDEND 2.499
STOCK DIVIDEND 1.999
Go To Top